G-Hemodialysis B

G-Hemodialysis B is an established, machine-proportioned component used together with an acid concentrate and purified water to prepare the final bicarbonate dialysate used during hemodialysis. Its principal, FDA-recognized use is:

• Correction/buffering of metabolic acidosis in patients with end-stage renal disease (ESRD) or acute kidney injury who require maintenance or acute hemodialysis.
• As a routine, guideline-supported constituent of the dialysate bath in essentially all modern bicarbonate hemodialysis, replacing older acetate-based systems because it is better tolerated hemodynamically.

G-Hemodialysis B is not intended to treat acidosis independent of the hemodialysis procedure and has no approved indication outside the dialysis circuit.

Bicarbonate Component [HCO3 Hemodialysis Solution] is typically supplied as a concentrated aqueous solution (or as a dry/powder cartridge reconstituted by the dialysis machine) containing sodium bicarbonate as the principal buffering ingredient, sometimes combined with a small amount of sodium chloride. It is one part of a two-part concentrate system (an acid concentrate and this bicarbonate concentrate) that the hemodialysis machine's proportioning pumps mix with purified water in a fixed ratio to generate the final dialysate.

G-Hemodialysis B is the bicarbonate-containing part of a hemodialysis dialysate concentrate system. During hemodialysis, blood is passed through a dialyzer (artificial kidney) across a semi-permeable membrane from a dialysate solution prepared by mixing G-Hemodialysis B and an acid concentrate with water in the specific ratio defined by the dialysis machine manufacturer. The resulting dialysate contains a physiologic bicarbonate concentration that diffuses into the patient's blood to correct the metabolic acidosis that accompanies chronic and acute kidney failure.

G-Hemodialysis B is a device-associated solution intended solely for use within the hemodialysis delivery system by trained dialysis personnel; it is never administered orally or by direct injection.

Renal replacement therapy solution; hemodialysis dialysate concentrate (bicarbonate component) — G-Hemodialysis B is classified as an alkalinizing/buffering agent used specifically in the extracorporeal hemodialysis circuit.

Mechanism of Action

When Bicarbonate Component [HCO3 Hemodialysis Solution] is proportioned with the acid concentrate and water inside the dialysis machine, it generates a dialysate with a bicarbonate concentration close to or above normal physiologic serum levels (typically prescribed in the range of 25-40 mEq/L). Because the dialysate bicarbonate concentration is higher than the patient's plasma bicarbonate in metabolic acidosis, bicarbonate ions diffuse down their concentration gradient across the dialyzer membrane from dialysate into blood, buffering excess hydrogen ions and correcting the acid-base disturbance of renal failure. Small amounts of acetate or citrate in the acid concentrate are also metabolized to bicarbonate, contributing an additional buffering effect.

Pharmacokinetics

Bicarbonate Component [HCO3 Hemodialysis Solution] itself is not systemically absorbed as a conventional drug; rather, bicarbonate ion transfer occurs by diffusion across the dialyzer membrane during each hemodialysis session, with the amount transferred determined by the concentration gradient, dialysate flow rate, membrane characteristics, and treatment duration.

G-Hemodialysis B is administered exclusively as part of the extracorporeal hemodialysis circuit:

• Connected to the dialysis machine's proportioning system by trained dialysis nurses/technicians.
• Automatically mixed with the matching acid concentrate and treated (RO) water in the ratio specified by the machine manufacturer.
• Delivered as dialysate that flows countercurrent to blood across the dialyzer membrane for the duration of each hemodialysis session.

G-Hemodialysis B must never be given orally, by direct intravenous injection, or by any route outside the validated hemodialysis delivery system.

Because G-Hemodialysis B determines the bicarbonate load delivered during dialysis, it can interact clinically with certain medicines and conditions:

• Digoxin and other cardiac glycosides: Rapid correction of acidosis and accompanying shifts in potassium and calcium during hemodialysis with G-Hemodialysis B-containing dialysate can increase susceptibility to digoxin toxicity and arrhythmias; potassium/calcium should be monitored closely in patients on digoxin.
• Calcium and active vitamin D supplements: A higher bicarbonate dialysate (from G-Hemodialysis B) combined with calcium-containing binders or vitamin D analogues can increase the risk of metabolic alkalosis and calcium-phosphate precipitation; dosing of these agents may need adjustment.
• Citrate-based anticoagulation used during dialysis: Citrate is also metabolized to bicarbonate; using it together with G-Hemodialysis B-based dialysate increases the risk of metabolic alkalosis, so bicarbonate concentration is often reduced when citrate anticoagulation is used.
• Other alkalinizing agents (e.g., oral sodium bicarbonate): Concurrent use with a dialysate prepared from G-Hemodialysis B can compound the risk of overcorrection and metabolic alkalosis.

Adverse effects associated with G-Hemodialysis B-based dialysate generally result from the physiologic shifts of hemodialysis itself or from improper concentration/mixing rather than a direct drug toxicity:

• Intradialytic hypotension
• Muscle cramps
• Nausea, vomiting, headache
• Dialysis disequilibrium syndrome (confusion, restlessness, rarely seizures) with rapid correction of acidosis
• Metabolic alkalosis if the bicarbonate concentration is set too high or mixing is incorrect
• Hypokalemia and hypocalcemia (with risk of muscle twitching/tetany) related to alkalosis
• Cardiac arrhythmias, particularly if electrolyte disturbances from incorrect proportioning occur

G-Hemodialysis B itself is a dialysate component rather than a systemically dosed drug, so no formal pregnancy category applies. Hemodialysis is used in pregnant women with end-stage renal disease when clinically necessary, and the dialysate bicarbonate concentration produced using G-Hemodialysis B is individualized by the treating nephrologist with more frequent, intensive monitoring during pregnancy. G-Hemodialysis B-based dialysate should be used in pregnancy only under close obstetric and nephrology supervision, with the prescribed dialysate composition adjusted based on maternal acid-base and electrolyte status. There is no specific restriction on use during lactation, but breastfeeding mothers on hemodialysis should be managed jointly by their nephrologist and pediatrician.

G-Hemodialysis B must be prepared, connected, and proportioned strictly according to the hemodialysis machine and concentrate manufacturer's instructions, and only by appropriately trained dialysis personnel. Key precautions include:

• Always confirm that the acid concentrate paired with G-Hemodialysis B is the one specifically validated for that combination; incorrect pairing can cause precipitation of calcium/magnesium carbonate crystals, which can damage the dialysis circuit or embolize.
• Verify proportioning ratios and conductivity/pH on the dialysis machine before and during each treatment.
• Monitor serum bicarbonate, electrolytes (potassium, calcium, sodium), and acid-base status regularly, especially after any change in the prescribed G-Hemodialysis B-based dialysate bicarbonate concentration.
• Once concentrate containers are opened or bicarbonate solutions/cartridges are prepared, use within the time frame specified by the manufacturer, as bicarbonate solutions can support bacterial growth and endotoxin formation if held too long.
• G-Hemodialysis B is intended solely for use within the validated hemodialysis delivery system and must never be administered by any other route.

"Overdose" in the context of G-Hemodialysis B refers to excessive bicarbonate delivery from an incorrectly prescribed or incorrectly mixed dialysate, which can produce metabolic alkalosis. Features may include confusion, muscle twitching or tetany, decreased respiratory drive, and cardiac arrhythmias related to accompanying hypokalemia or hypocalcemia. If excessive bicarbonate delivery or symptoms of alkalosis are suspected during or after a hemodialysis session using G-Hemodialysis B-based dialysate, treatment should be stopped or the dialysate composition corrected immediately, the patient should be assessed urgently by the dialysis team/physician, and emergency medical services should be contacted if there are severe symptoms (e.g., arrhythmia, seizure, altered consciousness). There is no specific home antidote; management is supportive and must occur under direct medical/dialysis-unit supervision.

Store at room temperature (below 30°C), protected from direct light, freezing, and excessive heat, as specified by the manufacturer. Keep containers tightly closed until use and keep out of reach of children. Once opened or mixed, use within the time period stated in the product's instructions for use.

Renal impairment: G-Hemodialysis B is used specifically because the patient already has significant renal impairment (ESRD or acute kidney injury requiring hemodialysis); the dialysate bicarbonate concentration is individualized rather than dosed by a separate renal-adjustment scale.

Hepatic impairment: No specific adjustment to G-Hemodialysis B-based dialysate composition is established for hepatic impairment; general acid-base and electrolyte monitoring applies.

Elderly: No specific dose adjustment beyond individualized prescription; elderly patients may be more sensitive to intradialytic hypotension and electrolyte shifts and should be monitored closely.

Pediatric patients: Used in children requiring hemodialysis, with the dialysate bicarbonate concentration individualized to the child's size, machine compatibility, and acid-base status by a pediatric nephrologist; see Pediatric Use.

G-Hemodialysis B is used for the full duration of each hemodialysis session (typically about 3-5 hours per session for patients on chronic maintenance hemodialysis, usually performed two to three times weekly) and is continued long-term for as long as the patient requires renal replacement therapy, since it is a routine component of every hemodialysis treatment rather than a course of medicine with a defined start and stop date.

Depending on the product format, G-Hemodialysis B may be supplied as a ready-to-use liquid concentrate or as a dry powder/cartridge (e.g., a bicarbonate "bibag" or powder canister) that the hemodialysis machine automatically reconstitutes by dissolving it with an internally generated stream of purified (reverse-osmosis) water immediately before or during use. Reconstitution must occur only within the dialysis machine's validated bicarbonate mixing system, following the manufacturer's instructions for use; manual reconstitution outside this system is not appropriate.

Bicarbonate Component [HCO3 Hemodialysis Solution] belongs to the class of hemodialysis dialysate concentrates / renal replacement therapy solutions, specifically the bicarbonate (alkalinizing buffer) component used opposite an acid concentrate.

Bicarbonate Component [HCO3 Hemodialysis Solution], once proportioned into the final dialysate, establishes a bicarbonate concentration gradient across the dialyzer's semi-permeable membrane that is higher in the dialysate than in the patient's acidotic blood. Bicarbonate ions diffuse from the Bicarbonate Component [HCO3 Hemodialysis Solution]-derived dialysate into the blood, buffering hydrogen ions and raising plasma bicarbonate and pH toward normal, while urea, creatinine, and other uremic solutes diffuse in the opposite direction from blood into dialysate.

G-Hemodialysis B-based dialysate is used in pediatric patients with end-stage renal disease or acute kidney injury who require hemodialysis. There is no separate pediatric drug dose; instead, the dialysate bicarbonate concentration achieved using G-Hemodialysis B is individualized by a pediatric nephrologist based on the child's body size, blood flow rate, dialyzer characteristics, and pre-dialysis acid-base status, using dialysis equipment validated for pediatric use. As with adults, safety depends entirely on correct proportioning by trained pediatric dialysis staff; formal dose-ranging safety and efficacy data specific to G-Hemodialysis B as an isolated agent (outside the dialysis procedure) have not been separately established.